uniQure Proposes $150M Offering and Reports 79–100% Seizure Reduction Data
QURE•uniQure has launched a $150 million underwritten public offering of ordinary shares, with a 30-day underwriter option for an additional $22.5 million, subject to market conditions. In early AMT-260 epilepsy data, three patients achieved 79–100% seizure reductions with no serious safety events.
1. Proposed Public Offering Details
uniQure has commenced an underwritten public offering of $150 million in ordinary shares and pre-funded warrants, with all securities to be sold by the company and completion contingent on market and other conditions.
2. Underwriter Option Terms
The company granted bookrunning managers a 30-day option to purchase up to an additional $22.5 million of ordinary shares on the same terms, with Leerink Partners and Stifel serving as bookrunners.
3. Early AMT-260 Epilepsy Data
In an early clinical evaluation, three patients treated with AMT-260 experienced 79–100% fewer seizures and reported no serious adverse events, supporting advancement of the temporal lobe epilepsy therapy.
